Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD164 molecule, sialomucin (CD164)
- Target
- CD164
- Molecular classification
- Cell adhesion molecule, Transmembrane sialomucin, CD molecule (Cluster of Differentiation)
01
Overview
CD164 (Sialomucin core protein 24, Endolyn) is a type I transmembrane sialomucin and cell adhesion molecule that regulates the proliferation, adhesion, and migration of hematopoietic progenitor cells, and modulates muscle development through interactions with CXCR4 and cell-cell adhesion mechanisms. It is implicated in stem cell biology, cancer metastasis, and is used as a diagnostic and therapeutic biomarker in multiple disease contexts. CD164 is highly glycosylated, displaying carbohydrate-dependent epitopes, and may mediate key cell contact and recognition events via its extracellular domains. Aberrant expression or mutation is associated with malignancy and sensorineural hearing loss.
- Other names
- Sialomucin core protein 24EndolynMUC24MGC-24v
02
Mechanism of action
Antibodies targeting carbohydrate-dependent epitopes modulate cell adhesion and proliferation; interference with CXCR4-mediated migration and homing (mainly experimental/biotherapeutic).
03
Biological functions
Regulation of cell adhesionRegulation of cell proliferationRegulation of cell migrationMyoblast differentiation and fusion (myogenesis)Regulation of hematopoiesis (blood cell development)Interaction with chemokine receptor CXCR4 (niche homing, migration)
04
Disease associations
Cancer (promotes tumorigenicity, prostate cancer metastasis, Sezary syndrome)Deafness/autosomal dominant sensorineural hearing lossOther roles: potential biomarker in hematologic malignancies, regulator in stem cell migration and homing
05
Safety considerations
Off-target effects due to broad expression in tissues and involvement in essential cell adhesion/migration processes.Specificity challenges when targeting CD164 therapeutically.Potential impairment of hematopoiesis or muscle regeneration.
06
Interacting drugs
Monoclonal antibodies (experimental)
07
Biomarkers
Marker for hematopoietic stem and progenitor cells (HSPC)Elevated expression as a marker in certain cancers (Sezary syndrome, prostate cancer metastasis)
Beyond the preview
Go deeper on CD164 molecule, sialomucin (CD164).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD164 molecule, sialomucin (CD164).